The Catalyst Brief
Daniel Cho
Author

Daniel Cho

Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.

148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry

Page 6 of 13

Gilead’s Trodelvy Gains FDA First-Line Approval in Triple-Negative Breast Cancer, Raising Stakes in Competitive MarketRegulatory & Policy

Gilead’s Trodelvy Gains FDA First-Line Approval in Triple-Negative Breast Cancer, Raising Stakes in Competitive Market

The FDA has granted Trodelvy, an antibody-drug conjugate from Gilead Sciences, a significant label expansion as a first-line therapy for triple-negative breast cancer (TNBC). This regulatory milestone puts Gilead on closer footing against competitors AstraZeneca and Daiichi Sankyo, intensifying the commercial and scientific race in the ADC space for breast cancer.

Daniel ChoDaniel ChoJun 25, 2026
Jubilant HollisterStier Faces FDA Rebuke Over Quality and Investigation Lapses: A Deeper Look at Regulatory Risks in Contract ManufacturingRegulatory & Policy

Jubilant HollisterStier Faces FDA Rebuke Over Quality and Investigation Lapses: A Deeper Look at Regulatory Risks in Contract Manufacturing

Jubilant HollisterStier recently received a formal warning letter from the US FDA over a series of lapses—including delayed investigation into mold contamination and broader quality unit shortfalls—compelling the company to reassess practices across global operations. This incident lays bare the ongoing high stakes in regulatory compliance for the contract manufacturing sector and offers key insights into the enduring challenges faced by organizations providing essential drug supply services.

Daniel ChoDaniel ChoJun 24, 2026
Tennessee Pharmacies See Rising Sales of Potent Ivermectin Led by Controversial DoctorRegulatory & Policy

Tennessee Pharmacies See Rising Sales of Potent Ivermectin Led by Controversial Doctor

In Tennessee, pharmacies have experienced a remarkable increase in sales of potent formulations of the antiparasitic drug ivermectin. This market growth is largely driven by an anti-vaccine doctor who has publicized his use of the drug and actively encourages others to follow suit. The expansion of this controversial market underscores persistent challenges for regulators, the medical community, and public health officials as they confront misinformation and lax pharmacy oversight.

Daniel ChoDaniel ChoJun 20, 2026
New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer DrugBiotech Innovation

New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug

The latest $27 million financing for MultiValent Biotherapies represents a significant advance for dual-targeting prostate cancer therapies. The company’s clinical-stage asset utilizes a peptide conjugate designed to simultaneously target both PSMA and folate receptor alpha, aiming to overcome resistance and improve outcomes for patients with advanced prostate cancer.

Daniel ChoDaniel ChoJun 17, 2026
What’s Flowing Beneath the World Cup: How Verily’s Wastewater Monitoring Could Catch the Next OutbreakMedical Technology

What’s Flowing Beneath the World Cup: How Verily’s Wastewater Monitoring Could Catch the Next Outbreak

As global attention focuses on the World Cup, Verily is piloting a novel approach to public health surveillance: testing wastewater in host cities for traces of key pathogens. This initiative, targeting viruses and bacteria like RSV, measles, and norovirus, could enable public health officials to identify outbreaks days before they manifest in clinics and hospitals.

Daniel ChoDaniel ChoJun 16, 2026
Sanofi Wins Type 1 Diabetes Nod for Tzield After Requesting to Revoke CNPVRegulatory & Policy

Sanofi Wins Type 1 Diabetes Nod for Tzield After Requesting to Revoke CNPV

Sanofi secured approval for Tzield in treating type 1 diabetes following a strategic withdrawal from the Commissioner’s National Priority Voucher program, which highlights the evolving regulatory landscape and ongoing scrutiny around expedited drug development programs.

Daniel ChoDaniel ChoJun 15, 2026
STAT+: AMA and Lawmakers Push Back on AI Care Denials: A Critical ExaminationRegulatory & Policy

STAT+: AMA and Lawmakers Push Back on AI Care Denials: A Critical Examination

Growing reliance on artificial intelligence in health insurance claim adjudication has prompted significant pushback from both the American Medical Association and lawmakers. As debates intensify, oversight and scrutiny of AI in healthcare administration are reaching a pivotal climax—with profound implications for patient care, provider autonomy, and the role of industry watchdogs.

Daniel ChoDaniel ChoJun 12, 2026
‘2030 Scares Me to Death’: Credit Analysts Warn Healthcare CFOs of Imminent Financial StormBiopharmaceutical Industry

‘2030 Scares Me to Death’: Credit Analysts Warn Healthcare CFOs of Imminent Financial Storm

Panelists at the HFMA annual conference delivered a dire message to healthcare financial leaders: the 2030s could bring unprecedented disruption as demographic shifts, shrinking reimbursements, and artificial intelligence rapidly reshape the industry. The window for bold, transformative action is closing fast, with potentially existential consequences for hospitals and health systems.

Daniel ChoDaniel ChoJun 11, 2026
FDA Approves First New Sunscreen Ingredient in a Generation: What This Means for U.S. Consumers and the Dermatology CommunityRegulatory & Policy

FDA Approves First New Sunscreen Ingredient in a Generation: What This Means for U.S. Consumers and the Dermatology Community

Federal regulators' decision to approve a novel sunscreen ingredient, bemotrizinol, signals a critical benchmark for sun safety in the United States. This policy move could reshape how the public and dermatology experts approach UV protection, with ramifications that extend across consumer health, industry innovation, and regulatory practice.

Daniel ChoDaniel ChoJun 9, 2026